DeepSee

Patient-derived microtumors (PDM) and autologous immune cells from tumor tissue will be treated with chemo- and immunotherapeutic agents, followed by proteo-genomic single cell analysis and generation of custom algorithms to identify treatment-induced changes in cellular PDM composition. Per flow cytometry, gene expression as well as the cytokine analyses in combination with next-generation sequencing based T cell receptor analysis will identify T cell receptors prone to infiltrate PDM. Bioinformatics analysis tools including integration of named datasets will be developed. A service offering for PDM analysis at the single cell level will be jointly developed and marketed.